Healthcare Industry News: protein therapeutics
News Release - June 8, 2006
Altus Pharmaceuticals Hires Dr. Burkhard Blank as Senior Vice President of Medicine, Regulatory Affairs and Project ManagementCAMBRIDGE, Mass.--(HSMN NewsFeed)--June 8, 2006--Altus Pharmaceuticals Inc. (Nasdaq: ALTU ), a biopharmaceutical company developing and commercializing oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that Burkhard Blank, M.D. has been appointed Senior Vice President Medicine, Regulatory Affairs and Project Management. In this role, Dr. Blank will be responsible for clinical development, medical affairs, regulatory affairs and quality assurance as well as project management.
"I am very pleased that Burkhard brings to Altus his extensive expertise in international project management, clinical development, and regulatory affairs," said Sheldon Berkle, President and CEO of Altus. "In his previous position as Senior Vice President for Medicine and Drug Regulatory Affairs at Boehringer Ingelheim Pharmaceuticals USA, Burkhard successfully managed the many components of an extensive clinical research program. This will be vital to Altus as we work to advance our two lead programs, ALTU-135 and ALTU-238, which we expect to enter pivotal Phase III clinical trials in the second half of this year."
While at Boehringer Ingelheim USA, Dr. Blank was responsible for a staff of 600 and an annual recruitment of 8,000-10,000 patients in the North and South America region. Prior to his position in the USA, he held a number of positions with increasing levels of responsibility at Boehringer's head office in Ingelheim, Germany, the most recent as Head of Division International Project Management and Drug Regulatory Affairs (DRA). In this capacity, he founded the International Project Management Department, which had worldwide responsibility for the planning and monitoring of all Phase I-IV development projects and for all international regulatory submissions. Dr. Blank was also a member of Boehringer's International Development Committee, which was responsible for steering their global drug development portfolio. He holds a medical degree in internal medicine from Universitaet Marburg, Germany.
About Altus Pharmaceuticals Inc.:
Altus Pharmaceuticals, headquartered in Cambridge, MA is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The Company's website is http://www.altus.com.
Source: Altus Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.